Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ObePso-S: Secukinumab in Plaque Psoriasis
NCT03055494Phase 4Completed
- Sponsor
- Novartis
- Start
- Apr 2017
- Primary completion
- Apr 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of secukinumab in plaque psoriasis, sponsored by Novartis. Started Apr 2017; status: completed.
02
Drugs
secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03055494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03055494.